KR20240101593A9 - 단백질 복합체의 조성물 및 이들의 이용 방법 - Google Patents

단백질 복합체의 조성물 및 이들의 이용 방법

Info

Publication number
KR20240101593A9
KR20240101593A9 KR1020247016162A KR20247016162A KR20240101593A9 KR 20240101593 A9 KR20240101593 A9 KR 20240101593A9 KR 1020247016162 A KR1020247016162 A KR 1020247016162A KR 20247016162 A KR20247016162 A KR 20247016162A KR 20240101593 A9 KR20240101593 A9 KR 20240101593A9
Authority
KR
South Korea
Prior art keywords
compositions
methods
protein complexes
complexes
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016162A
Other languages
English (en)
Korean (ko)
Other versions
KR20240101593A (ko
Inventor
존 토마스 멀리건
샤논 리 오카다
저스틴 리차드 킬브루
다이앤 루이스 홀렌바우
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20240101593A publication Critical patent/KR20240101593A/ko
Publication of KR20240101593A9 publication Critical patent/KR20240101593A9/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247016162A 2021-11-17 2022-11-17 단백질 복합체의 조성물 및 이들의 이용 방법 Pending KR20240101593A9 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280494P 2021-11-17 2021-11-17
US63/280,494 2021-11-17
PCT/US2022/080043 WO2023092006A1 (en) 2021-11-17 2022-11-17 Compositions of protein complexes and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20240101593A KR20240101593A (ko) 2024-07-02
KR20240101593A9 true KR20240101593A9 (ko) 2025-12-10

Family

ID=84981857

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016162A Pending KR20240101593A9 (ko) 2021-11-17 2022-11-17 단백질 복합체의 조성물 및 이들의 이용 방법

Country Status (11)

Country Link
US (1) US20240366776A1 (https=)
EP (1) EP4433097A1 (https=)
JP (1) JP2024544757A (https=)
KR (1) KR20240101593A9 (https=)
CN (1) CN118555973A (https=)
AU (1) AU2022390563A1 (https=)
CA (1) CA3238260A1 (https=)
IL (1) IL312802A (https=)
MX (1) MX2024005948A (https=)
TW (1) TW202330628A (https=)
WO (1) WO2023092006A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024273454A1 (en) * 2023-05-16 2025-11-27 F. Hoffmann-La Roche Ag Pd-1-regulated il-2 immunocytokine and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201482A (en) * 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
WO2019129053A1 (zh) * 2017-12-26 2019-07-04 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
IL298136A (en) * 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them

Also Published As

Publication number Publication date
JP2024544757A (ja) 2024-12-04
AU2022390563A1 (en) 2024-05-30
WO2023092006A1 (en) 2023-05-25
EP4433097A1 (en) 2024-09-25
MX2024005948A (es) 2024-06-11
TW202330628A (zh) 2023-08-01
IL312802A (en) 2024-07-01
US20240366776A1 (en) 2024-11-07
CN118555973A (zh) 2024-08-27
KR20240101593A (ko) 2024-07-02
CA3238260A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
GB2621482B (en) Compositions of protein complexes and methods of use thereof
EP4240168A4 (en) DAIRY-TYPE COMPOSITIONS AND RELATED PROCESSES
DK4267105T3 (da) Antistofsammensætninger og fremgangsmåder til anvendelse deraf
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
PT3697810T (pt) Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
EP4399306A4 (en) PAH COMPOSITIONS AND MODULATION METHODS
EP4499149A4 (en) PROTEIN DEGRADING AGENTS AND THEIR USES
EP4304774A4 (en) CEMENT COMPOSITIONS AND PROCESSES THEREOF
PL4208046T3 (pl) Kompozycje i sposoby
EP4192958A4 (en) COMPOSITIONS AND METHODS FOR INCREASING PROTEIN EXPRESSION
IL309079A (en) Methods and compositions
EP4146151A4 (en) FURANIC SURFACTANT COMPOSITIONS AND METHODS
EP4463173A4 (en) POSTBIOTIC COMPOSITIONS AND METHODS
EP4172388A4 (en) BARCODE METHODS AND COMPOSITIONS
IL311301A (en) Anti-siglec-6 antibodies and methods of use thereof
IL311867A (en) Trem compositions and methods of use
EP4373915A4 (en) PROTEIN COMPOSITIONS AND THEIR PRODUCTION PROCESSES
EP4065161A4 (en) HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIES
EP4084784A4 (en) Compositions and methods
KR20240101593A9 (ko) 단백질 복합체의 조성물 및 이들의 이용 방법
IL317275A (en) Collagen compositions and methods of use thereof
IL311750A (en) Feed additive compositions and methods for using the same
EP3952909A4 (en) COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS
EP4392037A4 (en) THERAPEUTIC COMPOSITIONS AND ASSOCIATED METHODS
EP4423142A4 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2A ANTIBODIES

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-3-3-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-3-3-P10-P19-oth-PG1701

Patent document republication publication date: 20251210

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1020240101593

Gazette reference publication date: 20240702